Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience

How much primary tumor metabolic volume reduction is required to improve outcome in stage III... Purpose We analysed a correlation between pre- to post-treatment primary tumour metabolic volume (PT-MV) reduction on 18F- FDG-PET/CT and survival in non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy (CRT). Methods Sixty consecutive patients with NSCLC stage IIIA-B (UICC 7th edition), treated with chemoradiotherapy, who underwent 18F-FDG-PET/CT at the same institution before and 6 weeks after treatment, were analysed. Different metabolic response values were investigated on their correlation with survival parameters: complete response (100% PT-MV reduction); major response (80–99% PT-MV reduction); moderate response (50–79% PT-MV reduction); minor response (1–49% PT-MV reduction) and non-response (no change or increase in uptake). Results From 60 patients, 52 (87%) had repeat PET/CT scans 6 weeks after completion of CRT. Complete metabolic response (CR) was reached in ten (17%), whereas major and moderate metabolic responses occurred in 16 (27%) and 15 (25%) patients, respectively. Four patients (7%) had minor metabolic response. Non-response was documented in seven patients (12%). Median overall survival (MS) for the entire cohort was 17 months (95% CI: 11.9–22.1 months). MS according to the different metabolic response values was as follows: 34 months (95% CI: 0–84.1); 22 months (95% CI: 14.2–29.8); 12 months (95% CI: 0.4–23.6); 11 months (95% CI: http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Nuclear Medicine and Molecular Imaging Springer Journals

How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/how-much-primary-tumor-metabolic-volume-reduction-is-required-to-bJzfpLnqck
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1619-7070
eISSN
1619-7089
DOI
10.1007/s00259-018-4063-7
Publisher site
See Article on Publisher Site

Abstract

Purpose We analysed a correlation between pre- to post-treatment primary tumour metabolic volume (PT-MV) reduction on 18F- FDG-PET/CT and survival in non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy (CRT). Methods Sixty consecutive patients with NSCLC stage IIIA-B (UICC 7th edition), treated with chemoradiotherapy, who underwent 18F-FDG-PET/CT at the same institution before and 6 weeks after treatment, were analysed. Different metabolic response values were investigated on their correlation with survival parameters: complete response (100% PT-MV reduction); major response (80–99% PT-MV reduction); moderate response (50–79% PT-MV reduction); minor response (1–49% PT-MV reduction) and non-response (no change or increase in uptake). Results From 60 patients, 52 (87%) had repeat PET/CT scans 6 weeks after completion of CRT. Complete metabolic response (CR) was reached in ten (17%), whereas major and moderate metabolic responses occurred in 16 (27%) and 15 (25%) patients, respectively. Four patients (7%) had minor metabolic response. Non-response was documented in seven patients (12%). Median overall survival (MS) for the entire cohort was 17 months (95% CI: 11.9–22.1 months). MS according to the different metabolic response values was as follows: 34 months (95% CI: 0–84.1); 22 months (95% CI: 14.2–29.8); 12 months (95% CI: 0.4–23.6); 11 months (95% CI:

Journal

European Journal of Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Jun 6, 2018

References

  • Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410
    Curran, WJJ; Paulus, R; Langer, CJ; Komaki, R; Lee, JS; Hauser, S
  • Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer
    Zhu, X; Liao, C; Penney, BC; Li, F; Ferguson, MK; Simon, CA
  • Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of non-small cell lung cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review
    Cremonesi, M; Gilardi, L; Ferrari, ME; Piperno, G; Travaini, LL; Timmerman, R
  • Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer
    Roengvoraphoj, O; Wijaya, C; Eze, C; Li, M; Dantes, M; Taugner, J
  • Standardized uptake decrease on [18F]-Fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for Resectable St
    Pottgen, C; Gauler, T; Bellendorf, A; Guberina, M; Bockisch, A; Schwenzer, N
  • 18F-Fluorodeoxyglucose/positron emission tomography predicts patterns of failure after definitive Chemoradiation therapy for locally advanced non-small cell lung cancer
    Ohri, N; Bodner, WR; Halmos, B; Cheng, H; Perez-Soler, R; Keller, SM
  • The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy
    Mattoli, MV; Massaccesi, M; Castelluccia, A; Scolozzi, V; Mantini, G; Calcagni, ML
  • Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer
    Wald, P; Mo, X; Barney, C; Gunderson, D; Haglund, AK; Bazan, J
  • Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer
    Roengvoraphoj, O; Wijaya, C; Eze, C; Li, M; Dantes, M; Taugner, J
  • Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the bronchial carcinoma therapy group
    Huber, RM; Flentje, M; Schmidt, M; Pollinger, B; Gosse, H; Willner, J
  • Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study
    Huber, RM; Borgmeier, A; Flentje, M; Willner, J; Schmidt, M; Manegold, C
  • GILT-A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer
    Flentje, M; Huber, RM; Engel-Riedel, W; Andreas, S; Kollmeier, J; Staar, S
  • Standard uptake value and metabolic tumor volume of (1)(8)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer
    Huang, W; Zhou, T; Ma, L; Sun, H; Gong, H; Wang, J
  • From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors
    Wahl, RL; Jacene, H; Kasamon, Y; Lodge, MA
  • Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival
    Wang, W-W; Wang, S-J; Zhou, Z-R
  • PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer
    Senan, S; Brade, A; Wang, L-H; Vansteenkiste, J; Dakhil, S; Biesma, B
  • Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
    Liang, J; Bi, N; Wu, S; Chen, M; Lv, C; Zhao, L
  • Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p
    Bradley, JD; Paulus, R; Komaki, R; Masters, G; Blumenschein, G; Schild, S
  • Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and leukemia group B
    Vokes, EE; Herndon, JE; Kelley, MJ; Cicchetti, MG; Ramnath, N; Neill, H
  • Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier oncology group and U.S. oncology
    Hanna, N; Neubauer, M; Yiannoutsos, C; McGarry, R; Arseneau, J; Ansari, R
  • Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
    Antonia, SJ; Villegas, A; Daniel, D; Vicente, D; Murakami, S; Hui, R
  • Effectiveness of respiratory-gated positron emission tomography/computed tomography for radiotherapy planning in patients with lung carcinoma - a systematic review
    Frood, R; Prestwich, R; Tsoumpas, C; Murray, P; Franks, K; Scarsbrook, A